KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Depreciation & Amortization (CF) (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with -$30000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 104.96% to -$30000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was -$30000.0, a 101.58% decrease, with the full-year FY2023 number at $1.9 million, down 31.26% from a year prior.
  • Depreciation & Amortization (CF) was -$30000.0 for Q1 2024 at Palvella Therapeutics, up from -$198000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $845000.0 in Q1 2022 to a low of -$198000.0 in Q4 2023.
  • A 5-year average of $553764.7 and a median of $609000.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 1161.9% in 2020, then plummeted 134.43% in 2023.
  • Palvella Therapeutics' Depreciation & Amortization (CF) stood at $688000.0 in 2020, then decreased by 11.48% to $609000.0 in 2021, then fell by 5.58% to $575000.0 in 2022, then tumbled by 134.43% to -$198000.0 in 2023, then skyrocketed by 84.85% to -$30000.0 in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Depreciation & Amortization (CF) are -$30000.0 (Q1 2024), -$198000.0 (Q4 2023), and $739000.0 (Q3 2023).